GIM
FATE icon

Granahan Investment Management’s Fate Therapeutics FATE Stock Holding History

Granahan Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-602,153
Closed -$6.08M – 170
2022
Q4 		$6.08M Buy
602,153
+275,734
+84% +$5.18M 0.19% 119
2022
Q3 		$7.32M Buy
326,419
+63,263
+24% +$1.83M 0.24% 106
2022
Q2 		$6.52M Buy
263,156
+58,211
+28% +$1.61M 0.22% 102
2022
Q1 		$7.95M Buy
204,945
+71,544
+54% +$2.77M 0.2% 106
2021
Q4 		$7.8M Buy
133,401
+58,909
+79% +$3.34M 0.16% 129
2021
Q3 		$4.42M Buy
+74,492
New +$5.84M 0.08% 159

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Granahan Investment Management's FATE Position: Q1 2023 in Review

Granahan Investment Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 602,153 shares — an estimated $6.08M sold.

Granahan Investment Management first reported a position in FATE in Q3 2021 and held it in 6 quarters. The position peaked at $7.95M in Q1 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Granahan Investment Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Granahan Investment Management sold 602,153 Fate Therapeutics shares in Q1 2023, an estimated $6.08M.
  • Granahan Investment Management first reported a position in Fate Therapeutics in Q3 2021 and held it in 6 quarters.
  • Granahan Investment Management's Fate Therapeutics position peaked at $7.95M in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Granahan Investment Management's 13F filing for Q1 2023, filed 15 May 2023.